Filing Details

Accession Number:
0001140361-17-043408
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-20 18:00:57
Reporting Period:
2017-11-16
Accepted Time:
2017-11-20 18:00:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885590 Valeant Pharmaceuticals International Inc. VRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1394923 John Paulson 1251 Avenue Of The Americas
New York NY 10020
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, No Par Value Acquisiton 2017-11-16 344,216 $14.40 21,183,251 No 4 P Indirect By Managed Funds
Common Stock, No Par Value Disposition 2017-11-16 344,216 $14.39 20,839,035 No 4 S Indirect By Managed Funds
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Managed Funds
No 4 S Indirect By Managed Funds
Footnotes
  1. John Paulson, the controlling person of Paulson & Co. Inc. ("Paulson"), serves on the board of directors of the Issuer. Paulson is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds"). John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission that such reporting person is the beneficial owner of any securities not directly owned by such reporting person.
  2. Represent rebalancing transactions between the Funds.